Sarcoidosis Diagnosis and Management

Definition and Pathophysiology

• Sarcoidosis is a chronic multi-system inflammatory disease characterized by the formation of non-caseating granulomas that can affect multiple organs, most commonly the lungs and intrathoracic lymph nodes, according to Rhinology 1
• The disease involves the formation of well-formed, concentrically arranged layers of immune cells, with a central core of macrophage aggregates and multinucleated giant cells, surrounded by loosely organized lymphocytes, as reported by the American Journal of Respiratory and Critical Care Medicine 2
• T cells play a central role with accumulation of CD4+ T cells, accompanied by release of IL-2 and formation of non-caseating granulomas, as noted by Rhinology 3
• Sarcoidosis granulomas are typically non-necrotic, though variants can present with a mixture of necrotic and non-necrotic granulomas, according to the American Journal of Respiratory and Critical Care Medicine 2

Epidemiology

• The age-adjusted incidence is approximately 11 cases per 100,000 in Caucasians, with higher prevalence in northern Europe, as reported by Rhinology 1
• In the United States, sarcoidosis is more prevalent in African Americans than whites, with women experiencing higher morbidity, mortality, and extrapulmonary involvement, according to Rhinology 1
• Mortality is significantly higher in some populations, with African American women having 2.4 times higher mortality compared to matched cohorts without sarcoidosis, as noted by the American Journal of Respiratory and Critical Care Medicine 4

Clinical Manifestations

• Löfgren's syndrome, lupus pernio, uveitis, and optic neuritis are highly probable clinical features for diagnosis, as reported by the American Journal of Respiratory and Critical Care Medicine 2
• Bilateral hilar adenopathy on imaging and perilymphatic nodules on chest CT are common findings, according to the American Journal of Respiratory and Critical Care Medicine 2
• Skin manifestations include lupus pernio, maculopapular lesions, erythema nodosum, and subcutaneous nodules, as noted by the American Journal of Respiratory and Critical Care Medicine 2, 5
• Upper respiratory tract involvement occurs in approximately 3-4% of patients with generalized disease, as reported by Rhinology 3
• Cardiac involvement can present with cardiomyopathy, atrioventricular block, or ventricular tachycardia, according to the American Journal of Respiratory and Critical Care Medicine 5

Diagnosis

• Diagnosis relies on compatible clinical and radiologic presentation, pathologic evidence of non-caseating granulomas, and exclusion of alternative causes of granulomatous inflammation, as reported by the American Journal of Respiratory and Critical Care Medicine 2
• High-resolution CT scan of the chest, tissue biopsy from affected organs, and bronchoalveolar lavage showing lymphocytosis or elevated CD4:CD8 ratio are useful diagnostic tests, according to Rhinology 3 and the American Journal of Respiratory and Critical Care Medicine 2, 5

Treatment

• Many patients with asymptomatic bilateral hilar lymphadenopathy have self-limited disease and do not require treatment, as noted by the American Journal of Respiratory and Critical Care Medicine 6

Sarcoidosis and Hematologic Alterations

Introduction to Sarcoidosis and Hematologic Manifestations

• The American College of Rheumatology suggests that sarcoidosis can produce reactive thrombocytosis as part of the hematologic alterations associated with this systemic inflammatory disease, which includes anemia, leucocytosis, and thrombocytosis 7
• Reactive thrombocytosis is frequent in patients with active sarcoidosis, as part of the systemic inflammatory response, with a strength of evidence based on observational studies 7
• Pro-inflammatory cytokines released during the formation of non-caseating granulomas can stimulate platelet production, according to the American Thoracic Society, with a moderate level of evidence 8, 9

Pathophysiological Mechanisms

• Sarcoidosis is characterized by an abnormal immune response with accumulation of CD4+ T cells and release of pro-inflammatory cytokines such as IL-2 and TNF, as stated by the European Respiratory Society, with a high level of evidence 10, 7
• This inflammatory cascade can stimulate the bone marrow and cause reactive thrombocytosis, with a moderate level of evidence 7
• The non-caseating granulomas characteristic of sarcoidosis generate a state of chronic inflammation that can alter blood cell production, according to the American Thoracic Society, with a moderate level of evidence 8

Specific Hematologic Alterations

• In addition to thrombocytosis, sarcoidosis can cause anemia of chronic disease, which is common during active disease, as reported by the American College of Rheumatology, with a high level of evidence 7
• Sarcoidosis can also cause leucocytosis with marked neutrophilia, with a moderate level of evidence 7
• Coagulation disorders are less frequent but can occur, according to the American College of Rheumatology, with a low level of evidence 7

Diagnosis and Monitoring

• A complete blood count is recommended at baseline in all patients with sarcoidosis to detect hematologic alterations, as suggested by the American Thoracic Society, with a high level of evidence 9
• Platelet monitoring should be part of routine follow-up in patients with active sarcoidosis, with a moderate level of evidence 9

Therapeutic Considerations

• Treatment of thrombocytosis generally does not require specific intervention and resolves with control of underlying inflammation, as stated by the American College of Rheumatology, with a moderate level of evidence 7

Approach to Exclude Sarcoidosis

Diagnostic Criteria and Systematic Approach

• The American Thoracic Society recommends a systematic approach to exclude sarcoidosis, involving clinical assessment, tissue sampling, and laboratory testing to rule out other conditions that can mimic sarcoidosis 11, 12, 13
• The diagnosis of sarcoidosis is based on three major criteria: compatible clinical presentation, finding nonnecrotizing granulomatous inflammation in tissue samples, and exclusion of alternative causes of granulomatous disease 11, 12, 13
• Obtain tissue samples from accessible involved organs, such as lung or lymph node biopsies, to confirm the presence of nonnecrotizing granulomatous inflammation 11, 12
• Perform laboratory tests, including serum calcium, creatinine, and alkaline phosphatase, to exclude alternative diagnoses and monitor disease activity 12, 13
• For suspected cardiac involvement, cardiac MRI is suggested, and for suspected pulmonary hypertension, initial testing with transthoracic echocardiogram is recommended 11
• In patients with high clinical suspicion for sarcoidosis, lymph node sampling may not be necessary, but close clinical follow-up is required 12, 13
• For patients with suspected cardiac involvement, cardiac MRI is preferred over other imaging modalities, and for patients with suspected pulmonary hypertension, right heart catheterization should be performed if echocardiogram is suggestive of pulmonary hypertension 11

Etiology and Diagnostic Approach to Sarcoidosis

Etiologic Theories

• Current evidence indicates that sarcoidosis arises from an abnormal immune response to unidentified antigens in genetically predisposed individuals, with possible triggering by environmental exposures—including microbial agents—although the precise cause remains unknown. 14

• The American Thoracic Society and the American Heart Association formally define sarcoidosis as a disease of unknown cause/origin, reflecting consensus that no definitive etiologic factor has been identified. 15

• Identical clinical and pathologic features observed in berylliosis and aluminosis suggest that similar environmental exposures may act as triggers for sarcoidosis. 14

Diagnostic Recommendations

• Because the etiology is unknown, the diagnosis of sarcoidosis requires exclusion of alternative causes of granulomatous inflammation (e.g., infections, berylliosis, other granulomatous diseases) and must be supported by a compatible clinical presentation together with histologic evidence of non‑caseating granulomas. 16

Genetic and Environmental Risk Assessment in Sarcoidosis

Family History and Shared Exposures

• Environmental and dietary factors that are shared among family members may contribute to sarcoidosis risk to a similar extent as genetic factors, highlighting the importance of assessing shared exposures in relatives of affected patients. 17
• A comprehensive family history covering at least three generations is recommended to identify individuals at higher risk for sarcoidosis. 18

Polygenic Risk Scores (Research Context)

• Polygenic risk scores that include the MUC5B variant and other genetic markers show promise for stratifying risk of interstitial lung disease, but they have not been validated for sarcoidosis risk assessment and therefore should not be used in routine clinical practice. 19

Environmental Exposure Documentation

• Systematic documentation of environmental and occupational exposures—such as beryllium, aluminum, mold, and air pollution—is essential when evaluating sarcoidosis risk, as these factors can interact with genetic susceptibility. 19